News

Public · Published

Piper Sandler maintains Neurocrine Biosciences at Overweight, raises price target to $215 from $210

Piper Sandler kept its Overweight rating on Neurocrine Biosciences and raised its price target to $215 from $210, a 2.4% increase. The new target implies about 47.9% upside from the November 2 close of $145.35.

Published:

Updated:

What happened

Piper Sandler kept its Overweight rating on Neurocrine Biosciences and raised its price target to $215 from $210, a 2.4% increase. The new target implies about 47.9% upside from the November 2 close of $145.35.

Confirmed

Global impact / market context

A higher price target signals the analyst expects more future value from the shares, which can draw buyer interest. Because the target sits well above the recent close, it suggests the analyst sees the stock as underpriced relative to its prospects.

Analyst inference

Other recent analyst targets on the stock range from $150 to $207, so Piper Sandler's $215 is the most optimistic. That gap shows analysts disagree on value, and the spread of views itself can sway how investors position shares.

Analyst inference

What to watch

  1. Watch whether Neurocrine Biosciences shares move toward the $215 target, which implies 47.9% upside from the November 2 close of $145.35. Confirmed
  2. Watch whether other analysts raise their own targets after Piper Sandler's move, since the three most recent targets span $150 to $207. Proposed
  3. Watch upcoming company results for signs that support the analyst's higher target, since a wider gap between targets can mean more uncertainty about future profit. Analyst inference

Evidence

  • Original source link unavailable